

March 31, 2021

Dear Director Fowler:

Congratulations on your recent appointment as the new Director of the Center for Medicare and Medicaid Innovation (CMMI). We appreciate the significant experience that you bring to this role, look forward to your leadership, and welcome the opportunity to work with you on critical issues facing the healthcare community.

We support Congress and the Biden administration's decision to delay the onset of the Radiation Oncology Alternative Payment Model (RO APM) and assess its full impact, and as leading clinicians treating cancer across the country, we respectfully request that you specifically review the treatment of proton beam therapy under the model. For the reasons outlined below, we strongly believe that proton beam therapy should be excluded from the payment episode, which will have very significant unintended consequences on critical cancer treatments for patients. We applaud the President's commitment to prioritize cancer for the 1.7 million Americans diagnosed each year, and we appreciate his clear recognition that "proton beams can be used and not do as much damage" to critical normal tissues compared with conventional x-ray radiation therapy.<sup>1</sup>

During the previous consideration of the RO APM, we raised a number of important concerns and were disappointed to see that the final model did not adequately address those concerns. (*See **Attachment 1***). A number of our esteemed colleagues from Emory, Mayo Clinic, MD Anderson, The University of Pennsylvania and Washington University expressed this same view in a leading cancer publication just a few weeks ago.<sup>2</sup>

Proton therapy is an emerging radiation treatment modality that has the proven ability to reduce side effects for patients by limiting the amount of normal tissue exposed to radiation. Unlike conventional x-ray radiation, which has both entrance and exit doses, proton therapy delivers radiation to the target, with little to no radiation extending beyond the target. In addition, there is new evidence that proton therapy may have an enhanced biologic effect on tumors over conventional x-ray therapy. Although proton therapy can improve disease outcomes, reduce radiation toxicity, and improve quality of life for patients with cancer, it is now under significant financial constraints due to the decision by the prior administration to include proton therapy in the RO APM.

Under the previous analysis of hospital radiation oncology claims to determine the proposed bundled payment rate, the reviewed claims included very few proton treatments, as proton therapy accounted for < 1% of the total sample analyzed. Given the rarity of proton therapy in the data, the rate-setting methodology described in the proposed rule would not produce national payment rates for the disease sites treated by proton beam therapy in a manner that would appropriately reimburse providers for their costs. Currently, proton therapy as an emerging technology is a more costly treatment due, in part, to the higher cost of the capital equipment required to deliver it, the higher

---

<sup>1</sup> <http://transcripts.cnn.com/TRANSCRIPTS/2002/05/se.01.html>

<sup>2</sup> Baumann BC, Metz JM, Frank SJ, Mahajan A, Bradley JM. Stifling Innovation: Proton Therapy Should Be Excluded From the New Radiation Oncology Alternative Payment Model. ASCO Daily News, <https://dailynews.ascopubs.org/doi/10.1200/ADN.21.200441/full/>.

cost of maintaining a proton center, and the greater complexity of proton therapy treatment planning and delivery.

Data recently compiled by the National Association for Proton Therapy from proton centers mandated to participate in the Model show cuts in year 1 of the RO APM ranging from 24.8% to 45.9%. (See **Attachment 2**) Such a massive financial loss incurred in year 1 alone (of a 5-year model) would place proton centers in significant and immediate financial jeopardy. Although pediatric patients are excluded from the RO APM, they will nonetheless be affected, as fewer proton centers will be able to continue operations, limiting children's access to proton therapy, which is considered the optimal delivery method of radiation and clear standard of care for most pediatric malignancies. We must not forget the 9.1 million Americans under 65 years with disabilities covered under Medicare (16% of the total Medicare population) who would greatly benefit from treatments that could avoid long-term side effects and secondary malignancies.

Proton therapy is a high-value treatment for appropriately selected pediatric and adult patients; however, the Center for Medicare & Medicaid Innovation has postulated that the therapy as a whole is "low-value" without acknowledging the most recent published data over the last 4 years. Specifically, as proton therapy is a relatively new treatment modality, most multi-center and National Institutes of Health-funded data on proton therapy have just emerged in the past few years, and high-quality comparative effectiveness data are now available that clearly contradict the claim that proton therapy is "low-value." Moreover, **Attachment 3** illustrates how this clinical research directly applies to the Medicare beneficiaries fighting certain cancers. Coverage policies are rapidly evolving in favor of proton therapy. Proton therapy should be excluded from the RO APM to provide proton centers time to gather the necessary additional data on comparative effectiveness and to complete numerous ongoing randomized trials to further clarify proton therapy's value for patients with cancer. Many of the trials are funded by the National Cancer Institute who has committed tens of millions of dollars in these trials to definitely demonstrate that proton therapy improves survival and reduces toxicities for cancer patients across multiple cancer sites and patient populations.

In 2020 alone, several key studies demonstrated the promise of proton therapy in making significant and clinically meaningful reductions in acute toxicity in our patients. The study by Baumann et al published in *JAMA Oncology* found that in a cohort of 1,483 patients with solid malignancies treated with definitive chemoradiotherapy for nonmetastatic disease, proton therapy was associated with a statistically significant two-thirds reduction in acute grade  $\geq 3$  adverse events on propensity weighted analysis (RR 0.31, 95% CI [0.15, 0.66];  $p = 0.002$ ) and a significant reduction in the rate of Eastern Cooperative Oncology Group (ECOG) performance status decline from the start to the end of treatment (RR 0.51, 95% CI [0.37, 0.71];  $p < 0.001$ ) compared with the photon group.<sup>3</sup> Disease-free survival and overall survival were comparable between the two cohorts. Although the study was retrospective, the data on adverse events and survival were gathered prospectively, and 90% of the patients on the photon arm received the most advanced form of photon radiotherapy: IMRT. The cost-effectiveness was not reported in that study, but a two-thirds reduction in serious adverse events associated with hospitalizations would be expected to more than offset the higher upfront cost of proton therapy, as has been demonstrated for several disease sites. Additionally, this report suggests the intriguing opportunity to intensify treatments with proton therapy, which could,

---

<sup>3</sup> Baumann BC, Mitra N, Harton JG, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. *JAMA Oncol.* 2020;6:237-246

in turn, improve oncologic outcomes for patients who receive chemoradiotherapy. With fewer patients experiencing a drop in their ECOG performance status during proton chemoradiotherapy, there could be cost savings to society, as more patients would be able to work during treatment and/or handle their own self-care, freeing up their families and caretakers to remain at their jobs. In 2020, we also saw the publication of a randomized prospective trial of proton compared with photon chemoradiotherapy for esophageal cancer by Lin et al in the *Journal of Clinical Oncology*.<sup>4</sup> Similar to the *JAMA Oncology* study, this trial found comparable oncologic outcomes but a statistically significant reduction in the primary endpoint of total toxicity burden in favor of the proton arm. Proton beam therapy was associated with 2.3-times lower total toxicity burden than photon therapy, as well patients having an average of 5 fewer days needed in the hospital for protons compared with photons to recover from their cancer treatment.

While the Lin et al and Baumann et al studies reported a benefit for proton therapy in reducing the risk of severe acute side effects, there is also excitement about the potential of proton therapy to limit late side effects of radiation, occurring months to years after treatment has completed. The study by Xiang et al also published in 2020 in the American Cancer Society's journal *Cancer* reported pooled data on second malignancies from the National Cancer Database on patients with a wide range of solid malignancies treated with definitive radiotherapy (450,373 patients). They found that proton therapy was associated with a statistically significant two-thirds reduction in the rate of second malignancies compared with photon therapy, including in the head-to-head analysis comparing proton therapy with IMRT. There is also recent data on long-term intelligence outcomes for proton compared with photon cranial radiation. In a study also published in 2020 by Kahalley et al in the *Journal of Clinical Oncology*, children treated with proton therapy for medulloblastoma exhibited superior long-term outcomes in global IQ, perceptual reasoning, and working memory compared with the photon-treated cohort ( $p < 0.05$  for all).<sup>5</sup>

In addition to these acute and late toxicity benefits of proton therapy over conventional radiation therapy, proton beam therapy has been shown across multiple disease sites to improve overall survival, either by reducing life-threatening toxicities, being more biologically potent at tumor killing, or allowing for more targeted and escalated doses of irradiation to be delivered directly to the tumor. In 2020, more literature was published supporting the survival benefit of proton therapy for select tumors, including the report by Cheng et al in the journal *Radiation Oncology* showing on a propensity-matched series a significant survival benefit to proton therapy over photon therapy ( $p=0.032$ ), for hepatocellular cancer while also cutting the rate of radiation-induced liver disease by over two thirds (11.8% vs. 36%,  $p=0.004$ ).<sup>6</sup>

There are many reasons to be excited about the promise of proton therapy and a compelling argument to be made that it is in the public's best interest to nurture proton therapy as a critical technology of the future that is part of the President's solution of ending cancer as we know it and thus exclude proton therapy from the RO APM.

---

<sup>4</sup> Lin SH, Hobbs BP, Verma V, et al. Randomized phase iib trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. *J Clin Oncol*. 2020;38:1569-1579.

<sup>5</sup> Kahalley LS, Peterson R, Ris MD, et al. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. *J Clin Oncol*. 2019;38:454-46.

<sup>6</sup> Cheng JY, Liu CM, Wang YM, et al. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. *Radiat Oncol*. 2020;15(1):159.

[PHYSICIAN SIGNATURES, AFFILIATED INSTITUTIONS]

*Attachment 1*

March 6, 2020 Letter to CMS Administrator from Cancer Care Physicians available at:  
<https://www.proton-therapy.org/wp-content/uploads/2021/02/Physician-letter-to-Administrator-Verma-3.6.20.pdf>

## Attachment 2

### Overview of Analysis

---

- As currently defined in the RO APM, thirteen proton therapy centers fall under the model
  - Mandated members span 8 different states
  - Centers by institution type:
    - ❖ 10 hospital based centers
    - ❖ 3 freestanding centers
- Requested center specific metrics by component
  - Case mix factor
  - Historical experience adjustment factor
  - Efficiency factor

### Cancer Types

---

- |                     |                        |
|---------------------|------------------------|
| ▪ Anal Cancer       | ▪ Head and Neck Cancer |
| ▪ Bladder Cancer    | ▪ Liver Cancer         |
| ▪ Bone Metastases   | ▪ Lung Cancer          |
| ▪ Brain Metastases  | ▪ Lymphoma             |
| ▪ Breast Cancer     | ▪ Pancreatic Cancer    |
| ▪ Cervical Cancer   | ▪ Prostate Cancer      |
| ▪ CNS Tumor         | ▪ Upper GI Cancer      |
| ▪ Colorectal Cancer | ▪ Uterine Cancer       |

*Focusing on five of the most common cancer types treated with proton beam therapy based on NAPT annual survey data\**

\* National Association for Proton Therapy Annual Survey – CY 2019 data

### Approach to Analysis

---

- Recreated the methodology for calculating the payment rates based on the Final Rule
- Assumptions
  - Incorporated a 2% quality withhold
  - Adjusted for the CY 2021 geographic adjustments
  - Modeled the impact of different trend factors
    - ❖ Due to lack of clarity on the cancer-specific trend factors, used a trend factor of 1 for each cancer type
- Incorporated the adjustments from the centers
  - To date, there was variability in the type of centers
    - ❖ Centers with 3 years experience vs. no experience
    - ❖ Centers with predominantly protons vs. centers with service mix


## Approach to Analysis

- Compared the technical component rates in **PY 1** to each center's historical reimbursement rates for technical component

$$\% \Delta = \frac{(\text{PY 1 TC Rates by Cancer}) - (\text{Historical TC Rates by Cancer})}{(\text{Historical TC Rates by Cancer})}$$

## Findings

### **PY 1 RO APM PROVIDER-SPECIFIC RATES VS. AVERAGE HISTORICAL RATES (N=6)**



*All centers facing substantial cuts vis-à-vis historical reimbursement rates*

## Key Observations

- On average, for PY 1, the percent change from historical proton rates to center specific rates under RO APM was **-36.0%**
  - Historical reimbursement based on a mix of fractionation protocol and technology schemes
  - Depending on the clinically appropriate protocol for the patient given their cancer, cuts in PY 1 may be even greater
  - Inefficient and efficient practices are facing comparable cuts in payment rates, creating disincentive for efficiency
- Difference in rates may be exacerbated or mitigated based on the trend factors
- Effects of the adjustment factors inconsistent with expectations established based on the Final Rule
  - Not a muted glidepath to the national base rates
- Uncertainty and significant concern as to the impact in PY 2 – PY 5 given the estimated impact in PY 1

**Attachment 3**

Research Article	Median Age	Date Published
Lin SH, Hobbs BP, Verma V, et al. (2020). Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>J Clin Oncol</i> , 38(14), 1569–1579. <a href="https://doi.org/10.1200/JCO.19.02503">https://doi.org/10.1200/JCO.19.02503</a>	67	August 2020
Xiang M, Chang DT, Pollom EL. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. <i>Cancer</i> . 2020;126(15):3560-3568.	63	May 2020
Baumann BC, Mitra N, Harton JG, et al. (2020). Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. <i>JAMA Oncol</i> , 6(2), 237–246. <a href="https://doi.org/10.1001/jamaoncol.2019.4889">https://doi.org/10.1001/jamaoncol.2019.4889</a>	62 (66 for proton cohort)	December 2019
Van Rossum P, Deng W, Routman DM, et al. (2020). Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. <i>Pract Radiat Oncol</i> , 10(1), e16–e26. <a href="https://doi.org/10.1016/j.prro.2019.07.010">https://doi.org/10.1016/j.prro.2019.07.010</a>	63.1 +/- 10.7 years (Entire cohort)	July 2019
Rice SR, Li YR, Busch TM, et al (2019). A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma. <i>Photochem Photobiol</i> , 95(1), 411–418. <a href="https://doi.org/10.1111/php.13065">https://doi.org/10.1111/php.13065</a>	69	December 2018
Routman DM, Garant A, Lester SC, et al. (2019). A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. <i>Adv Radiat Oncol</i> , 4(1), 63–69. <a href="https://doi.org/10.1016/j.adro.2018.09.004">https://doi.org/10.1016/j.adro.2018.09.004</a>	66	September 2018
Vyfhuis M, Rice S, Remick J, et al. (2018). Reirradiation for locoregionally recurrent non-small cell lung cancer. <i>J Thorac Dis</i> , 10(Suppl 21), S2522–S2536. <a href="https://doi.org/10.21037/jtd.2017.12.50">https://doi.org/10.21037/jtd.2017.12.50</a>	n/a	August 2018
Verma V, Lin L, Simone CB, 2nd (2018). Proton Beam Therapy for Bronchogenic Adenoid Cystic Carcinoma: Dosimetry, Toxicities, and Outcomes. <i>Int J Part Ther</i> , 4(4), 1–9. <a href="https://doi.org/10.14338/IJPT-17-00014.1">https://doi.org/10.14338/IJPT-17-00014.1</a>	67	July 2018
Liao Z, Lee JJ, Komaki R, et al. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>J Clin Oncol</i> , 36(18), 1813–1822. <a href="https://doi.org/10.1200/JCO.2017.74.0720">https://doi.org/10.1200/JCO.2017.74.0720</a>	67	January 2018
Chang JY, Verma V, Li M, et al (2017). Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. <i>JAMA Oncol</i> , 3(8), e172032. <a href="https://doi.org/10.1001/jamaoncol.2017.2032">https://doi.org/10.1001/jamaoncol.2017.2032</a>	70	August 2017


Research Article	Median Age	Date Published
Chao HH, Berman AT, Simone CB, 2nd, et al. (2017). Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. <i>J Thorac Oncol</i> , 12(2), 281–292. <a href="https://doi.org/10.1016/j.jtho.2016.10.018">https://doi.org/10.1016/j.jtho.2016.10.018</a>	65	February 2017
Lester SC, Lin SH, Chuong M, et al. (2017). A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. <i>Int J Radiat Oncol Biol Phys</i> , 98(4), 820–828. <a href="https://doi.org/10.1016/j.ijrobp.2017.02.021">https://doi.org/10.1016/j.ijrobp.2017.02.021</a>	60	February 2017
Remick JS, Schonewolf C, Gabriel P, et al. (2017). First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clin Lung Cancer</i> , 18(4), 364–371. <a href="https://doi.org/10.1016/j.clcc.2016.12.009">https://doi.org/10.1016/j.clcc.2016.12.009</a>	65 (proton), 63 (IMRT)	December 2016
Higgins KA, O'Connell K, Liu Y, et al. (2017). National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <i>Int J Radiat Oncol Biol Phys</i> , 97(1), 128–137. <a href="https://doi.org/10.1016/j.ijrobp.2016.10.001">https://doi.org/10.1016/j.ijrobp.2016.10.001</a>	68	October 2016
McDonald MW, Liu Y, Moore MG, Johnstone PA. (2016). Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. <i>Radiat Oncol</i> (London, England), 11, 32. <a href="https://doi.org/10.1186/s13014-016-0600-3">https://doi.org/10.1186/s13014-016-0600-3</a>	46.7	February 2016
Cheng JY, Liu CM, Wang YM, et al. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. <i>Radiat Oncol</i> . 2020;15(1):159.	65.53(Mean)	June 2020
Makita C, Nakamura T, Takada A, et al. (2014). High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors. <i>Acta Oncol</i> (Stockholm, Sweden), 54(3), 307–314. <a href="https://doi.org/10.3109/0284186X.2014.948060">https://doi.org/10.3109/0284186X.2014.948060</a>	77	July 2014
Patel SH, Wang Z, Wong WW, et al. (2014). Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. <i>Lancet Oncol</i> , 15(9), 1027–1038. <a href="https://doi.org/10.1016/S1470-2045(14)70268-2">https://doi.org/10.1016/S1470-2045(14)70268-2</a>	57.7	June 2014
Kanemoto A, Okumura T, Ishikawa H, et al. (2014). Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non--small-cell lung cancer. <i>Clin Lung Cancer</i> , 15(2), e7–e12. <a href="https://doi.org/10.1016/j.clcc.2013.11.002">https://doi.org/10.1016/j.clcc.2013.11.002</a>	75	March 2014
Hoppe BS, Michalski JM, Mendenhall NP, et al. (2014). Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 120(7), 1076–1082. <a href="https://doi.org/10.1002/cncr.28536">https://doi.org/10.1002/cncr.28536</a>	66	December 2013

Research Article	Median Age	Date Published
Bush DA, Cheek G, Zaheer S, et al. (2013). High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. <i>Int J Radiat Oncol Biol Phys</i> , 86(5), 964–968. <a href="https://doi.org/10.1016/j.ijrobp.2013.05.002">https://doi.org/10.1016/j.ijrobp.2013.05.002</a>	73.2	August 2013
Chung CS, Yock TI, Nelson K, et al. (2013). Incidence of second malignancies among patients treated with proton versus photon radiation. <i>Int J Radiat Oncol Biol Phys</i> , 87(1), 46–52. <a href="https://doi.org/10.1016/j.ijrobp.2013.04.030">https://doi.org/10.1016/j.ijrobp.2013.04.030</a>	59	April 2013

  
\_\_\_\_\_  
Physician Signature


Christopher Sines, M.D.  
Printed Name

Hampton U. Proton Institute  
Institution

  
\_\_\_\_\_  
Physician Signature

Allan Thornton  
Printed Name

Hampton University Proton  
Institution Therapy Institute

  
\_\_\_\_\_  
Physician Signature

Bradford Hoppe, M.D.  
Printed Name

Mayo Clinic  
Institution

  
\_\_\_\_\_  
Physician Signature

Chris Hallemeier, M.D.  
Printed Name

Mayo Clinic  
Institution

  
\_\_\_\_\_  
Physician Signature

Anita Mahajan, M.D.  
Printed Name

Mayo Clinic  
Institution

  
\_\_\_\_\_  
Physician Signature

Nadia Laack, M.D.  
Printed Name

Mayo Clinic  
Institution

  
\_\_\_\_\_  
Physician Signature

Sameer Keole, MD  
Printed Name

Mayo Clinic  
Institution



Physician Signature

Arnab Chakravarti

Printed Name

OSU Wexner – James Cancer  
Hospital

Institution




Physician Signature

Jose G Bazan, M.D. M.S.

Printed Name

OSU Wexner – James Cancer  
Hospital

Institution




Physician Signature

Julia White

Printed Name

OSU Wexner – James Cancer  
Hospital

Institution



Physician Signature

Dukagjin M. Blakaj

Printed Name

OSU Wexner – James Cancer  
Hospital

Institution



Physician Signature

Douglas Martin

Printed Name

OSU Wexner – James Cancer  
Hospital

Institution

Thomas F DeLaney, MD

Physician Signature

Thomas F DeLaney

Printed Name

Francis H Burr Proton Therapy  
Center

Mass General

Institution



Physician Signature

Torunn Yock, MD

Printed Name

Francis H Burr Proton Therapy  
Center

Mass General

Institution



Physician Signature

DAVID MANSUR, MD

Printed Name

Case Western Reserve Univ.

Institution

Charles B. Simone, II  
Physician Signature

Charles B. Simone, II  
Printed Name

New York Proton Center and MSKCC  
Institution

J. Isabelle Choi  
Physician Signature

J. Isabelle Choi  
Printed Name

New York Proton Center and MSKCC  
Institution

Robert H. Press  
Physician Signature

Robert H. Press  
Printed Name

New York Proton Center and Mount Sinai  
Institution

Shaakir Hasan  
Physician Signature

Shaakir Hasan  
Printed Name

New York Proton Center and Montefiore  
Institution

Arpit M. Chhabra  
Physician Signature

Arpit M. Chhabra  
Printed Name

New York Proton Center  
Institution

Simon N. Powell  
Physician Signature

Simon N. Powell  
Printed Name

MSKCC and New York Proton Center  
Institution

Kaled M. Alektiar  
Physician Signature

Kaled M. Alektiar  
Printed Name

MSKCC and New York Proton Center  
Institution

Christopher A. Barker  
Physician Signature

Christopher A. Barker  
Printed Name

MSKCC and New York Proton Center  
Institution

Oren Cahlon  
Physician Signature

Oren Cahlon  
Printed Name

MSKCC and New York Proton Center  
Institution

Carla Hajj  
Physician Signature

Carla Hajj  
Printed Name

MSKCC and New York Proton Center  
Institution

Daniel Gorovets  
Physician Signature

Daniel Gorovets  
Printed Name

MSKCC and New York Proton Center  
Institution

Nancy G. Lee  
Physician Signature

Nancy Y. Lee  
Printed Name

MSKCC and New York Proton Center  
Institution

Annemarie F. Shepherd  
Physician Signature

Annemarie F. Shepherd  
Printed Name

MSKCC and New York Proton Center  
Institution

Suzanne L. Wolden  
Physician Signature

Suzanne L. Wolden  
Printed Name

MSKCC and New York Proton Center  
Institution

Y. Josh Yamada  
Physician Signature

Y. Josh Yamada  
Printed Name

MSKCC and New York Proton Center  
Institution

T. Jonathan Yang  
Physician Signature

T. Jonathan Yang  
Printed Name

MSKCC and New York Proton Center  
Institution

Shalom Kalnicki  
Physician Signature

Shalom Kalnicki  
Printed Name

Montefiore and New York Proton Center  
Institution

Jana L. Fox  
Physician Signature

Jana L. Fox  
Printed Name

Montefiore and New York Proton Center  
Institution

Madhur K. Garg  
Physician Signature

Madhur K. Garg  
Printed Name

Montefiore and New York Proton Center  
Institution

Rafi Kabarriti  
Physician Signature

Rafi Kabarriti  
Printed Name

Montefiore and New York Proton Center  
Institution

Keyur J. Mehta  
Physician Signature

Keyur J. Mehta  
Printed Name

Montefiore and New York Proton Center  
Institution

Nitin Ohri  
Physician Signature

Nitin Ohri  
Printed Name

Montefiore and New York Proton Center  
Institution

Justin Tang  
Physician Signature

Justin Tang  
Printed Name

Montefiore and New York Proton Center  
Institution

Kenneth Rosenzweig  
Physician Signature

Kenneth Rosenzweig  
Printed Name

Mount Sinai and New York Proton Center  
Institution

Richard Bakst  
Physician Signature

Richard Bakst  
Printed Name

Mount Sinai and New York Proton Center  
Institution

Stanislav Lazarev  
Physician Signature

Stanislav Lazarev  
Printed Name

Mount Sinai and New York Proton Center  
Institution

Sonam Sharma  
Physician Signature

Sonam Sharma  
Printed Name

Mount Sinai and New York Proton Center  
Institution


Brian K. Yeh  
Physician Signature

Brian K. Yeh  
Printed Name

Mount Sinai and New York Proton Center  
Institution



Nancy Price Mendenhall, M.D., FASTRO  
Professor and Associate Chair, UF Health Radiation Oncology  
Medical Director, UFHPTI



Randal H. Henderson, M.D., M.B.A.  
Professor, UF Health Radiation Oncology  
Associate Medical Director, UFHPTI  
Chief of Service of Radiation Oncology for Shands Jacksonville



William M. Mendenhall, M.D., FACR, FASTRO  
Professor, UF Health Radiation Oncology



R. Charles Nichols, Jr., M.D.  
Associate Professor, UF Health Radiation Oncology



Michael Rutenberg, M.D., PhD.  
Assistant Professor, UF Health Radiation Oncology



Raymond Mailhot, M.D., MPH  
Assistant Professor, UF Health Radiation Oncology



Eric Brooks, M.D., M.H.S  
Assistant Professor, UF Health Radiation Oncology



Daniel Indelicato, M.D.  
Professor, UF Health Radiation Oncology



Roi Dagan, M.D., MS  
Associate Professor, UF Health Radiation Oncology



Julie Bradley, M.D.  
Associate Professor, UF Health Radiation Oncology



Curtis Bryant, MD. MPH  
Assistant Professor, UF Health Radiation Oncology



Adam Holtzman, M.D.  
Assistant Professor, UF Health Radiation Oncology



Physician Signature

Ashish Chawla, M.D.  
Printed Name


Inova Schar Cancer Institute  
Institution




Physician Signature


Anvari Rao MD  
Printed Name


Inova Schar Cancer  
Institution Institute


  
Physician Signature  
JOSEPH KANG  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
Jessica Jutzy, MD, PhD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
Jason Slater, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
Ivan Namihas, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
Lilia Loredo, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
GARY KANG  
Printed Name  
Loma Linda University  
Medical Center  
Institution

  
Physician Signature  
David Bush, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
Jerry D. Slater, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
Physician Signature  
B. Rodney Jabola, MD  
Printed Name  
Loma Linda University  
Medical Center  
Institution


  
\_\_\_\_\_  
Physician Signature  
Michael Chuong  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Marcio Fagundes  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Noah Kalman  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution


  
\_\_\_\_\_  
Physician Signature  
Maria Amelia Rodrigues  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution


  
\_\_\_\_\_  
Physician Signature  
Martin Tom  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Joseph Panoff  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution


  
\_\_\_\_\_  
Physician Signature  
Jessika Contreras  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Rupesh Kotecha  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Adeel Kaiser  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Andre Abitbol  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Matthew Hall  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Alan Lewin  
\_\_\_\_\_  
Printed Name  
Miami Cancer Institute  
\_\_\_\_\_  
Institution



Physician Signature

Minessh Mehta, MD

Printed Name

Miami Cancer Institute

Institution



Physician Signature

Mark Storey MD

Medical Director Clinical Operations

Printed Name

Oklahoma Proton Center

Institution



Physician Signature

JOHN HAN-CHIH CHANG

Printed Name

MEDICAL DIRECTOR

OKLAHOMA PROTON CENTER

Institution

ASSOCIATE PROFESSOR  
UNIVERSITY OF OKLAHOMA

Physician

Printed

Institution



Physician Signature

Lane R. Rosen

Printed Name

Willis-Knighton Health System

Institution



Physician Signature

Sanford R. Katz

Printed Name

Willis-Knighton Health System

Institution



Physician Signature

Michael L. Durci

Printed Name

Willis-Knighton Health System

Institution




Physician Signature

Chiachien J. Wang

Printed Name

Willis-Knighton Health System

Institution



Physician Signature

Sergio Jaramillo

Printed Name

Willis-Knighton Health System

Institution

Karen Godette, MD  
Physician Signature  
KAREN GODETTE, MD  
Printed Name  
EMORY  
Institution

[Signature]  
Physician Signature  
Prakash Patel  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
SUNIL DUTTA  
Printed Name  
EMORY  
Institution

[Signature]  
Physician Signature  
Mark McDonald MD  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Joseph Swanson  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Jeffrey Bradley  
Printed Name  
Emory  
Institution

N. Esashvili  
Physician Signature  
Natia Esiasvili  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Sharon Kahn  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Sibo Tan  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Bill Stokes  
Printed Name  
Emory  
Institution

[Signature]  
Physician Signature  
Bree Eaton  
Printed Name  
Emory  
Institution

Kim Kim  
Physician Signature

Kim Keese  
Printed Name

UAB Radiation Therapy  
Institution

Robert Kim  
Physician Signature

ROBERT KIM  
Printed Name

UAB  
Institution

Ruby Meredith  
Physician Signature

Ruby Meredith  
Printed Name

UAB  
Institution

Arun George Paul  
Physician Signature

Arun George Paul  
Printed Name

UAB Radiation Oncology  
Institution

Samuel Marcom  
Physician Signature

Samuel Marcom  
Printed Name

UAB Radiation Oncology  
Institution

Sharon A. Spencer  
Physician Signature

Sharon A. Spencer  
Printed Name

UAB Radiation Oncology  
Institution

Kody Yang  
Physician Signature

KODY YANG  
Printed Name

UAB  
Institution

James Bonner  
Physician Signature

James Bonner  
Printed Name

UAB  
Institution

James W. Sneider III  
Physician Signature

James W. Sneider III  
Printed Name

UAB  
Institution

Hunter Beys  
Physician Signature

Hunter Beys  
Printed Name

UAB  
Institution

Adam Kole  
Physician Signature

Adam Kole  
Printed Name

UAB  
Institution

Physician Signature

Printed Name

Institution



Physician Signature

Georges Hobeika, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Jennifer K. Logan, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Rafael R. Mañon, MD

Printed Name

Orlando Health Cancer Institute  
Institution




Physician Signature

Catherine Mercado, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Naren Ramakrishna, MD, PhD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Eric Saunders, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Akash Nanda, MD, PhD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Justin Rineer, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Kaitlin Christopherson, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Cameron Swanick, MD

Printed Name

Orlando Health Cancer Institute  
Institution



Physician Signature

Patrick Kelly, MD, PhD

Printed Name

Orlando Health Cancer Institute  
Institution

Physician Signature  
Gregory S. Gustafson  
Printed Name  
Beaumont Health System  
Institution

Physician Signature  
J. Robertson  
Printed Name  
Beaumont Health  
Institution

Physician Signature  
Daniel Krauss  
Printed Name  
OUWB School of Medicine  
Institution

Physician Signature  
SIRISHA NANDALUR  
Printed Name  
BEAUMONT HEALTH  
Institution

Physician Signature  
Peter Y. Chen  
Printed Name  
Beaumont Health System  
Institution

Physician Signature  
Thomas Guemero MD PhD  
Printed Name  
OUWB School of Medicine  
Institution

Physician Signature  
Kwei C. Lee  
Printed Name  
OUWB School of Medicine  
Beaumont Health  
Institution

Physician Signature  
Joshua Dilworth MD, PhD  
Printed Name  
OUWB School of Medicine  
Beaumont Health Syst.  
Institution

Physician Signature  
Prakash Chinnayyan  
Printed Name  
OUWB School of Medicine  
Institution

Physician Signature  
Andrew Thompson  
Printed Name  
OUWB School of Medicine  
Beaumont Health  
Institution


Physician Signature  
Jannifer Stromberg MD  
Printed Name  
OUWB School of Medicine  
Beaumont Health System  
Institution

Physician Signature  
Tanya S Grillo  
Printed Name  
OUWB School of Medicine  
Beaumont Health  
Institution


Physician Signature  
Daniel Hamby MD, PhD  
Printed Name  
Beaumont Health  
Institution

Physician Signature  
Rohan Deraniyagala  
Printed Name  
Beaumont Health  
Institution


Physician Signature  
Thomas Quinn  
Printed Name  
Beaumont Health  
Institution



Physician Signature




Printed Name




Institution



Physician Signature



Printed Name



Institution

Physician Signature  
*Jae Lee*  
Printed Name  
Jae Lee  
Institution  
ProCure proton center


Physician Signature  
*Henry Tsai*  
Printed Name  
Henry Tsai  
Institution  
ProCure NJ

Physician Signature  
*Nicholas DeNunzio*  
Printed Name  
NICHOLAS DENUNZIO  
Institution  
ProCure NJ

Physician Signature  
*Edward Siffert*  
Printed Name  
EDWARD SIFFERT  
Institution  
ProCure

Physician Signature  
*Brian Chan*  
Printed Name  
Brian Chan  
Institution  
ProCure

Physician Signature  
*Ben Cooper*  
Printed Name  
Ben Cooper  
Institution  
NYU Langone Health



Physician Signature

Hesham E. Gayar

Printed Name

KCI-McLaren Flint

Institution



Physician Signature

Omar H. Gayar

Printed Name

KCI-McLaren Flint

Institution



Physician Signature

Christian Hyde

Printed Name

KCI-McLaren Flint

Institution

Adil Akthar, MD

Physician Signature

Adil Akthar, MD

Printed Name

Northwestern Medicine Proton  
Center

Institution

Vinai Gondi, MD

Physician Signature

Vinai Gondi, MD

Printed Name

Northwestern Medicine Proton  
Center

Institution

Stephen Mihalcik, MD

Physician Signature

Stephen Mihalcik, MD

Printed Name

Northwestern Medicine Proton  
Center

Institution

Bharat Mittal, MD

Physician Signature

Bharat Mittal, MD

Printed Name

Northwestern University /  
Northwestern Medicine Proton  
Center

Institution

Nasir Mohammed, MD,  
MBA

Physician Signature

Nasir Mohammed, MD, MBA

Printed Name

Northwestern Medicine Proton  
Center

Institution

Arpi Thukral, MD, MPH

Physician Signature

Arpi Thukral, MD, MPH

Printed Name

Northwestern Medicine Proton  
Center

Institution

John Breneman MD  
Physician Signature  
John Breneman  
Printed Name  
Cincinnati Childrens  
Institution

Kyle Wray  
Physician Signature  
Kyle Wray  
Printed Name  
Univ. of Cincinnati  
Institution

Luke Pater  
Physician Signature  
Luke Pater  
Printed Name  
Cincinnati Childrens  
Institution

Timothy D. Struve  
Physician Signature  
Timothy D. Struve  
Printed Name  
Univ of Cincinnati  
Institution

SORDAN KHANOFFA  
Physician Signature  
SORDAN KHANOFFA  
Printed Name  
UNIV OF CINCINNATI  
Institution

Sara Medek  
Physician Signature  
Sara Medek  
Printed Name  
Univ. of Cincinnati  
Institution

William Barrett  
Physician Signature  
William Barrett  
Printed Name  
Univ of Cincinnati  
Institution

Teresa Meier  
Physician Signature  
Teresa Meier  
Printed Name  
Univ of Cincinnati  
Institution

Emily Daugherty  
Physician Signature  
Emily Daugherty  
Printed Name  
University of Cincinnati  
Institution

Kevin Redmond MD  
Physician Signature  
Kevin Redmond MD  
Printed Name  
Univ of Cincinnati  
Institution

VINITA TAYLOR M.D.  
Physician Signature  
VINITA TAYLOR M.D.  
Printed Name  
University of Cincinnati  
Institution

RALPH VATNER MD  
Physician Signature  
RALPH VATNER  
Printed Name  
University of Cincinnati  
Institution

Physician Signature

Jing Zeng, MD  
Printed Name

Associate Professor,  
Dept. of Radiation  
Oncology, Univ. of  
Washington School of  
Medicine  
Medical Director, Seattle  
Cancer Care Alliance  
Proton Therapy Center  
Institution

Physician Signature

Lia M. Halasz, MD  
Printed Name

Attending Physician, University  
of Washington Medical Center,  
Seattle Cancer Care Alliance, and  
Harborview Medical Center  
Associate Professor,  
Departments of Radiation  
Oncology and Neurological  
Surgery  
Program Director, Radiation  
Oncology Residency  
University of Washington School  
of Medicine  
Institution

Physician Signature

Upendra Parvathaneni, MBBS,  
FRANZCR  
Printed Name

Associate Professor of Radiation  
Oncology, UW Medicine  
Institution

Physician Signature

Jay J. Liao, M.D.  
Printed Name

Associate Professor of  
Radiation Oncology, UW  
Medicine  
Institution

Physician Signature

George E. Laramore, PhD MD  
FACR  
Printed Name

Peter Wootton Endowed  
Professor of Radiation Oncology,  
UW Medicine  
Institution

Physician Signature

Smith "Jim" Apisarnthanarax, MD  
Printed Name

Medical Director, Seattle Cancer Care  
Alliance Radiation Oncology  
Institution

Physician Signature

Stephanie K. Schaub, M.D.  
Printed Name

Assistant Professor of  
Radiation Oncology, UW  
Medicine  
Institution

Physician Signature

Li-Ming C Fang  
Printed Name

Associate Professor, University of  
Washington  
Institution

Physician Signature

Ramesh Rengan, MD, PhD  
Printed Name

Professor and Chair  
Department of Radiation Oncology  
University of Washington School of  
Medicine  
Faculty Immunotherapy Integrated  
Research Center Fred Hutchinson  
Cancer Research Center  
Professor Clinical Research Division  
Fred Hutchinson Cancer Research  
Center  
Institution

  
\_\_\_\_\_  
Physician Signature


Kent Wallner  
\_\_\_\_\_  
Printed Name

University of Washington  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature

Nina A Mayer, MD, FASTRO,  
\_\_\_\_\_  
FAAAS

Printed Name Univ. of  
Washington, School of Medicine  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature  
Jonathan Chen  
\_\_\_\_\_  
Printed Name  
SCCA Proton Therapy Center  
\_\_\_\_\_  
Institution

  
\_\_\_\_\_  
Physician Signature

Simon S Lo, MB, ChB, FACR,  
\_\_\_\_\_  
FASTRO  
Printed Name

University of Washington,  
\_\_\_\_\_  
Medical Center  
Institution

  
Physician Signature

Brian Baumann, MD  
Printed Name

Washington Univ in St Louis  
Institution

  
Physician Signature

Shaked Badiyan  
Printed Name

Washington University  
Institution

  
Physician Signature

Jeff Michalski  
Printed Name

Washington University  
Institution

  
Physician Signature

Imran Zoberi  
Printed Name

Washington University  
Institution

  
Physician Signature

Hiram Gay  
Printed Name

Washington University  
Institution

  
Physician Signature

Matt Spraker  
Printed Name

Washington University  
Institution

  
Physician Signature

Christopher D. Abraham, MD  
Printed Name

Washington University School  
Of Medicine St. Louis  
Institution

  
Physician Signature

Alexander Lin  
Printed Name

Washington University  
Institution

Andrew K. Lee MD

Physician Signature

ANDREW K. LEE  
Printed Name

US Oncology Network  
Institution

Jared Sturgeon

Physician Signature

Jared Sturgeon, MD, PhD  
Printed Name

US Oncology Network  
Institution

Scott Ackerman

Physician Signature

Scott Ackerman  
Printed Name

Ackerman Cancer Ctr.  
Institution

Babita Jyoti

Physician Signature

BABITA JYOTI  
Printed Name

ACKERMAN CANCER CENTER  
Institution

Ryan Perkins

Physician Signature

RYAN PERKINS  
Printed Name

ACKERMAN CANCER CENTER  
Institution

James R. Gray MD

Physician Signature

James R. Gray  
Printed Name

Tennessee Oncology  
Institution  
Provision

Josh Mondschein MD

Physician Signature

Josh Mondschein MD  
Printed Name

Tennessee Oncology  
Institution  
Provision